DSE/BXPHARMA (DSE/BXPHARMA)

Dhaka Stock Exchange: DSE/BXPHARMA · BDT

BDT 143

+0.20 (+0.1%)· Recorded snapshot

Market cap	63.8B
Revenue (ttm)	53.9B
Net income (ttm)	8.6B
EPS (ttm)	BDT 19.4
Shares out	446.1M
P/E (trailing)	7.4x
P/E (forward)	7.4x
Dividend	BDT 4.75 (3.32%)
Volume	312,831
Beta	0.30

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 53.9B
Net income (ttm): 8.6B
EPS (ttm): BDT 19.4
P/E (trailing): 7.4x
P/E (forward): 7.4x
Market cap: 63.8B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 13:30 UTC

Forward P/E7.4

P25 n/aP50 n/aP75 n/a

Trailing P/E7.4

P25 n/aP50 n/aP75 n/a

ROE14.7

P25 n/aP50 n/aP75 n/a

ROIC14.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DSE/BXPHARMA indicators

Market & fundamental data

Available fields

247

Groups with data

Currency

BDT

Showing 247 of 247 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	BDT
Country	Bangladesh
Country code	BD
Earnings date	2026-11-03
Employees	1,223
Employees change	101
Employees growth	9%
Enterprise value	BDT 65.2B
Exchange	Dhaka Stock Exchange
Financial currency	BDT
Financial report date	2026-03-31
First seen	2026-05-10
Fiscal year end	June
Founded	1976
Industry	Pharmaceutical Preparations
Is primary listing	Yes
ISIN number	BD0453BXPH04
Last earnings date	2026-06-23
Last refreshed	2026-10-29
Last stock split date	2020-11-26
Last stock split type	Forward
Market cap	BDT 63.8B
Next earnings date	2026-11-03
Price	BDT 143.00
Price currency	BDT
SIC code	2834
Stock price date	2026-10-28
Symbol	dse/BXPHARMA
Website	https://beximcopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	12.81x
Average P/E ratio (3Y)	8.47x
Average P/E ratio (5Y)	11.06x
Earnings yield	13.56%
EV/Earnings	7.54x
EV/EBIT	5.76x
EV/EBITDA	4.94x
EV/FCF	9.01x
EV/Sales	1.21x
FCF / EV yield	11.1%
FCF yield	11.35%
Forward P/E	7.36x
Graham number	242.32346
Graham upside	69.46%
Industry P/E	9.78x
Lynch fair value	BDT 263.06
Lynch upside	83.96%
P/B ratio	1x
P/E ratio	7.38x
P/FCF ratio	8.81x
P/OCF ratio	6.09x
P/S ratio	1.18x
Price / tangible book value	1.17x
Price/EBITDA ratio	4.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.01%
EBITDA margin	24.31%
Effective tax rate	22.36%
FCF margin	13.43%
Gross margin	47.42%
Operating margin	21.01%
Pretax margin	20.99%
Profit margin	16.04%
Profit per employee	BDT 7.1M
Revenue per employee	BDT 44.1M
ROA	9.22%
ROA (5Y)	7.36%
ROCE	15.75%
ROE	14.71%
ROE (5Y)	12.27%
ROIC	14.31%
ROIC (5Y)	10.96%
Tax / revenue	4.69%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	28.9%
EPS growth (Q)	28.96%
EPS growth (QoQ)	-5.84%
EPS growth 10Y	16.04%
EPS growth 3Y	24.55%
EPS growth 5Y	13.57%
FCF growth	130.26%
FCF growth (Q)	188.55%
FCF growth (QoQ)	200.17%
FCF growth 3Y	36.82%
FCF growth 5Y	14.45%
Gross profit growth	18.35%
Gross profit growth (Q)	15.05%
Gross profit growth 3Y	15.68%
Gross profit growth 5Y	14.17%
Net income growth	28.9%
Net income growth (Q)	28.96%
Net income growth (QoQ)	-5.84%
Net income growth 3Y	24.55%
Net income growth 5Y	13.57%
OCF growth	74.86%
OCF growth (Q)	67.38%
OCF growth (QoQ)	11%
OCF growth 10Y	19.02%
OCF growth 3Y	23.47%
OCF growth 5Y	13.36%
Operating income growth	22.94%
Operating income growth (Q)	23.95%
Operating income growth 3Y	20.45%
Operating income growth 5Y	12.58%
Revenue growth	12.43%
Revenue growth (Q)	8.08%
Revenue growth (QoQ)	-2.7%
Revenue growth 10Y	15.32%
Revenue growth 3Y	12.4%
Revenue growth 5Y	13.79%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	BDT -3.2B
Depreciation and amortization	BDT 1.8B
EBIT	BDT 11.3B
EBITDA	BDT 13.1B
EPS	BDT 19.39
FCF per share	BDT 16.23
Financing cash flow	BDT -4.5B
Free cash flow	BDT 7.2B
Gross profit	BDT 25.6B
Income taxes	BDT 2.5B
Investing cash flow	BDT -3.6B
Net borrowing	BDT -4.3B
Net cash flow	BDT 2.3B
Net income	BDT 8.6B
Operating income	BDT 11.3B
Revenue	BDT 53.9B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.3
Book value per share	BDT 134.60
Debt / EBITDA	0.24
Debt / equity	0.05
Debt / FCF	0.44
Goodwill	BDT 674.6M
Interest coverage	16.64
Long-term assets	BDT 50.7B
Long-term liabilities	BDT 7.8B
Net cash (debt)	BDT 2.6B
Net cash / market cap	4.11%
Net debt / EBITDA	-0.2
Net debt / equity	-0.04
Net debt / FCF	-0.36
Piotroski F-Score	8
Property, plant and equipment	BDT 45.2B
Shareholders' equity	BDT 64.1B
Tangible book value	BDT 54.7B
Tangible book value per share	BDT 122.58
Total assets	BDT 78.7B
Total cash	BDT 5.8B
Total debt	BDT 3.2B
Total liabilities	BDT 14.6B
WACC	6.43%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.7
Current assets	BDT 28.1B
Current liabilities	BDT 6.8B
Current ratio	4.13
Inventory turnover	1.86
Net working capital	BDT 17.3B
Quick ratio	1.4
Working capital	BDT 21.3B
Working capital turnover	3.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend growth	0%
Dividend growth (10Y)	17.98%
Dividend growth (3Y)	10.72%
Dividend growth (5Y)	6.3%
Dividend growth years	1
Dividend payment years	1
Dividend payout frequency	Annual
Dividend per share	BDT 4.75
Dividend yield	3.32%
Ex-dividend date	2026-08-03
FCF payout ratio	29.26%
Last dividend	BDT 4.75
Payout ratio	2.45%
Shareholder yield	3.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	104.82%
10Y return CAGR	9.73%
10Y total return	152.93%
150-day SMA	BDT 135.79
15Y price change	179.67%
15Y return CAGR	9.01%
15Y total return	264.88%
1D price change	0.14%
1M price change	-2.79%
1M total return	-2.79%
1W price change	-2.05%
1W total return	-2.05%
1Y price change	27.57%
1Y return CAGR	31.74%
1Y total return	31.71%
20-day SMA	BDT 144.69
200-day SMA	BDT 130.37
20Y price change	779.19%
20Y return CAGR	13.04%
20Y total return	1,060.38%
3M price change	-2.79%
3M total return	0.37%
3Y price change	-2.19%
3Y return CAGR	2.87%
3Y total return	8.85%
50-day SMA	BDT 146.49
50-day SMA vs 200-day SMA	50over200
52-week high	BDT 158.50
52-week high date	2026-07-08
52-week low	BDT 99.50
52-week low date	2026-01-05
5Y price change	-33.27%
5Y return CAGR	-5.01%
5Y total return	-22.67%
6M price change	23.28%
6M total return	27.28%
All-time high	BDT 255.40
All-time high date	2021-10-06
All-time low	BDT 6.84
All-time low date	2003-10-16
Average true range (ATR)	BDT 2.98
Average volume	483.1K
Beta (1Y)	0.67
Beta (2Y)	0.11
Beta (5Y)	0.3
Change from 52-week high	-9.78%
Change from 52-week low	43.72%
Change from all-time high	-44.01%
Change from all-time low	1,990.34%
Change from open	-1.17%
Day's gap	1.33%
Dollar volume	BDT 44.7M
High price	BDT 144.70
Low price	BDT 142.00
Monthly RSI	58.53
Open price	BDT 144.70
Position in 52-week range	37.04%
Previous close	BDT 142.80
Price vs 150-day SMA	5.31%
Price vs 20-day SMA	-1.16%
Price vs 200-day SMA	9.69%
Price vs 50-day SMA	-2.38%
Relative volume	0.65
RSI	42.41
Sharpe ratio	0.76
Sharpe ratio (3Y)	0.12
Sharpe ratio (5Y)	-0.06
Sortino ratio	1.48
Sortino ratio (3Y)	0.38
Sortino ratio (5Y)	0.12
Volume	312.8K
Weekly RSI	98.67
YTD price change	40.06%
YTD total return	44.61%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares change (QoQ)	0%
Shares held by institutions	0.08%
Shares outstanding	446.1M

Deeper analysis on DSE/BXPHARMA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DSE/BXPHARMA report

Is a complete DSE/BXPHARMA research report available?

No complete published report is available for dse/BXPHARMA (DSE/BXPHARMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

DSE/BXPHARMA (DSE/BXPHARMA)

Price

Financial snapshot

Fair-value bridge

Latest news · DSE/BXPHARMA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DSE/BXPHARMA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DSE/BXPHARMA

Frequently asked questions